Rheumatoid Arthritis is the Most Likely Diagnosis
Based on the clinical presentation of morning hand stiffness, inflammatory joint involvement (ankle pain and swelling), and positive rheumatoid factor, this 80-year-old patient most likely has rheumatoid arthritis, and should be started immediately on methotrexate 7.5-10 mg orally weekly with consideration of short-term low-dose glucocorticoids.
Diagnostic Reasoning
The clinical picture strongly points to RA rather than other conditions:
- Morning stiffness in the hands is a hallmark inflammatory symptom 1, 2
- Positive rheumatoid factor supports the diagnosis (present in 40-60% of RA patients at diagnosis) 1
- Normal uric acid effectively rules out gout as the primary diagnosis 3
- The symmetric pattern affecting hands and ankle is characteristic of RA 1
Critical caveat: While positive RF supports RA, it alone never proves the diagnosis 2. The diagnosis is clinical, based on characteristic joint swelling in the appropriate distribution (proximal interphalangeal, metacarpophalangeal, wrist joints) combined with inflammatory symptoms 1, 4.
At age 80, this patient falls within the peak incidence range (55-75 years) for RA 1.
Immediate Treatment Algorithm
First-Line Therapy (Start Immediately)
Methotrexate remains the cornerstone initial DMARD 5, 6, 1:
- Start with methotrexate 7.5-10 mg orally weekly 1
- Escalate to 20-25 mg weekly within 4-8 weeks 1
- Add folic acid supplementation (standard practice to reduce side effects)
Adjunctive Glucocorticoid Therapy
Consider adding short-term glucocorticoids for rapid symptom control 5, 1:
- Prednisone 5-7.5 mg daily, tapered and discontinued within 3 months 1, OR
- Single intramuscular injection of methylprednisolone 80-160 mg 1
- Intra-articular glucocorticoids for the swollen ankle if monoarticular flare 5
The 2026 PANLAR guidelines strongly recommend intra-articular glucocorticoids for oligoarticular flares 5, which would be appropriate for this patient's ankle involvement.
Important Management Considerations
If Gastrointestinal Intolerance Develops
Switch to subcutaneous methotrexate rather than abandoning the drug 5. Parenteral administration has:
- Higher bioavailability
- Reduced GI side effects
- Better disease activity reduction
- Improved adherence 5
Alternative First-Line DMARDs (if methotrexate contraindicated)
- Sulfasalazine 2-4 g/day, OR
- Leflunomide 20 mg/day 1
Treatment Goals and Monitoring
Target remission or low disease activity 5, 6, 1:
- Reassess at 3 months: Aim for at least 50% improvement in disease activity 1
- Reassess at 6 months: Target remission or low disease activity (measured by Clinical Disease Activity Index) 1
- With optimal first-line treatment, approximately 40% achieve remission within 6 months 1
Escalation Strategy if Inadequate Response
If the patient fails to achieve treatment targets with methotrexate monotherapy or combination conventional DMARDs 6:
Add or switch to biological DMARDs:
- TNF-α inhibitors
- IL-6 receptor inhibitors
- Anti-CD20 agents (rituximab)
- Costimulation inhibitors (abatacept)
Or add JAK inhibitors (avoid in patients at high risk for thromboembolism, cardiovascular disease, or malignancy—important consideration in an 80-year-old) 1
With addition of biologics or JAK inhibitors, overall remission or low disease activity rates increase to approximately 80% 1.
Critical Pitfalls to Avoid
- Do not delay DMARD initiation waiting for additional testing—early treatment (ideally within 6 weeks of symptom onset) prevents irreversible joint destruction 1, 7
- Do not use chronic low-dose glucocorticoids as monotherapy—they are adjunctive only and should be discontinued within 3 months 5, 1
- Do not assume normal uric acid excludes all diagnoses—it effectively rules out gout but doesn't change the RA diagnosis 3
- Screen for tuberculosis, hepatitis B/C before starting biologics if escalation becomes necessary 6, 8
Age-Specific Considerations
At 80 years old, carefully monitor for: